Currently, there is no effective pharmacological treatment for non-functioning pituitary adenoma, including gonadotroph adenoma (GPA). Recent findings showed that an alternative pharmacological treatment targeted at somatostatin receptor 3 may be promising, which required accurate diagnosis of GPA before surgery. This study aimed to evaluate the utility of magnetic resonance fingerprinting (MRF) in the pre-surgical differentiation of GPA from non-functioning, non-gonadotropin adenoma (NGPA). The results showed that GPAs have significantly higher T1 and T2 values in the solid tumor than NGPA, suggesting that MRF may have potential for diagnosing GPA and benefit its treatment plan.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords